Anti-Dectin-1 Antibody Conjugate for Allergy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic and inflammatory diseases, such as asthma and allergic rhinitis, are often non-specific and may compromise immune function or have limited duration of effect, necessitating the development of targeted therapies to modulate Th2-type cell responses and IgE levels.
Innovation Solution
Administration of a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment operatively linked to a TLR agonist, specifically Pam3CSK4, to decrease Th2-type cell responses and IgE levels, thereby preventing or treating allergic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-specific immunosuppressants are used to alleviate allergic reactions, then allergic symptoms are reduced, but the host's immunity to pathogenic infections is compromised
Solution Approach 1:
The patent uses Dectin-1 as an intermediary receptor that specifically recognizes beta-glucans from fungal cell walls. By targeting this specific pathway, the treatment mediates anti-allergic effects through dendritic cell modulation while preserving immunity to bacterial and viral pathogens, thus resolving the contradiction between reducing allergic reactions and maintaining protective immunity
Solution Approach 2:
The invention applies local quality by specifically targeting allergic responses through Dectin-1 pathway modulation rather than using systemic immunosuppression. The treatment selectively affects Th2-type immune responses and IgE production while leaving other immune functions intact, providing localized therapeutic action with minimal global immune suppression
2Object-affected harmful factors
If conventional allergy medications are used, then symptoms are alleviated, but the duration of effect is limited and efficacy is restricted to a subset of the population
Solution Approach 1:
The patent employs preliminary action by using Dectin-1-targeted therapy to modulate dendritic cell function and skew immune responses before allergic reactions fully develop. This preventive approach addresses the underlying immune dysregulation rather than merely treating symptoms, leading to longer-lasting therapeutic effects and potentially reduced need for repeated dosing
3Object-affected harmful factors
If non-specific immunosuppressants are administered, then allergic reactions are reduced, but the treatment lacks specificity and may cause broader immune compromise
Solution Approach 1:
The patent introduces Dectin-1 as a specific intermediary that mediates the therapeutic effect. This receptor is selectively engaged by beta-glucan-containing compounds, enabling targeted modulation of allergic responses through dendritic cells without affecting other immune pathways, thus eliminating the harmful side effect of broad immune compromise
Solution Approach 2:
The invention implements local quality by directing therapeutic action specifically at the Dectin-1 pathway involved in allergic responses. This localized approach affects only the relevant immune mechanisms (Th2 responses, IgE production) while preserving the functionality of other immune systems, thereby avoiding the generation of harmful broad-spectrum immune suppression
Data Source
Figure 1
Figure 1
Figure 1
AI summary
Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment thereof operatively linked to a TLR agonist.